Wednesday, November 11, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 9, 2026

Ask an Advisor: I'm 47 With $1.87 Million But I'm ‘Burned Out' From My Stressful Career. Can I Retire Early at 51?

View original at finance.yahoo.com
Ask an Advisor: I'm 47 With $1.87 Million But I'm ‘Burned Out' From My Stressful Career. Can I Retire Early at 51? Help me! I read the column frequently-huge fan!I'm 47, married, and severely burned out after 25+ years in a fast-paced and stressful field…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Actual Social Security benefit is likely to be meaningfully lower than statement estimates for early retirees

    80% confidence
  • Social Security statement estimates won't be accurate for early retirees because they assume continued earnings at current level

    80% confidence
  • People tend to spend more in early retirement years when active, with spending slowing with age and picking back up for health expenses

    80% confidence
  • Most people with Scott's assets and income sources would be able to comfortably retire at 51

    80% confidence
  • Retirement success is driven by whether assets can reliably support spending, not by portfolio size alone

    80% confidence
  • Plans to sell primary residence in around three years and buy something all cash somewhere warm

    80% confidence
  • If spending needs are similar to average person, Scott can almost certainly retire at 51 with his assets

    80% confidence
  • Scott is probably looking at a very active period for the next 15-20 years based on his age

    80% confidence
  • Severely burned out after 25+ years in a fast-paced and stressful field

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com